Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06766305

QL1706 Combined With SOX Used in Theperioperative Treatment

Phase Ib/II Clinical Study of QL1706 Combined With SOX Perioperative Treatment for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Sponsor: Xiangdong Cheng

Conditions Esophagogastric Junction Cancers Gastric Cancers

Interventions QL1706 combined with SOX

Updated 3 times since 2025 Last updated: Jun 12, 2025 Started: Mar 21, 2025 Primary completion: Feb 28, 2026 Completion: Jun 30, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Esophagogastric Junction Cancers and Gastric Cancers and is currently actively recruiting participants. Xiangdong Cheng leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Jul 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — Jul 2025 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2025 — Apr 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xiangdong Cheng

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China